Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Oct 25;2(5):e000338. doi: 10.1161/JAHA.113.000338

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Figure 1. — Benefits of bone marrow mononuclear cell (BM‐MNC) therapy. A and B, Intracoronary BM‐MNC delivery led to a 6.7% point improvement in left ventricular ejection fraction (LVEF) at 6 months in the BOOST clinical trial and to 5.5% improvement in LVEF at 4 months in the REPAIR‐AMI clinical trial, respectively. C, Kaplan–Meier event‐free survival analysis in the REPAIR‐AMI at 12 months showed better survival from death, recurrence of myocardial infarction, or revascularization procedures and (D) death, recurrence of myocardial infarction, or rehospitalization for heart failure in the BM‐MNC group. Panel A was reproduced with permission from Wollert et al, Lancet, 2004,²¹ panel B from Schachinger et al, New England Journal of Medicine, 2006,²² and panels C and D from Schachinger et al, European Heart Journal, 2006.²³ BOOST indicates BOne marrOw transfer to enhance ST‐elevation infarct regeneration; REPAIR‐AMI, Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction.